EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases

Mostafa Akbarzadeh-Khiavi iD, Amir-Hossein Olfati, Azam Safary iD

Advanced Pharmaceutical Bulletin · 15.06.2026 · 16 (2) · 332-342

DOI: 10.34172/apb.46844 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 10.05.2026. Verfasst von Mostafa Akbarzadeh-Khiavi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Die Arbeit nennt 155 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune-mediated inflammatory diseases (IMIDs) are chronic disorders characterized by dysregulated immunity and loss of self-tolerance. Although significant progress has been made in the management of IMIDs, challenges such as drug resistance, immunogenicity, and limited accessibility continue to impede clinical outcomes. Achieving sustained remission necessitates a transition toward precision medicine that addresses fundamental disease mechanisms. This study examines recent advances in molecular interventions, including cytokine inhibitors, kinase modulators, and B-cell therapies, and emphasizes how these approaches improve remission rates and reduce relapses. Additionally, emerging platforms such as RNA therapeutics, nanomedicine, and chimeric antigen receptor (CAR) cell therapies are discussed, with a focus on their potential to enhance efficacy and prolong clinical response duration. Integrating these innovations with artificial intelligence to identify therapeutic targets, predict patient responses, and optimize drug development is essential to realizing truly personalized, more successful treatments for IMIDs.

Schlagwörter

Stichwörter der Autor:innen

Immune toleranceImmune-mediated inflammatory diseasesPrecision medicineTargeted molecular therapies

Autor:innen und Institutionen

  • Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

ORCID-Profile: Mostafa Akbarzadeh-Khiavi, Azam Safary

Zitieren

APA

Akbarzadeh-Khiavi, M., Olfati, A. H., & Safary, A. (2026). Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases. Advanced Pharmaceutical Bulletin, 16(2), 332-342. https://doi.org/10.34172/apb.46844

Vancouver

Akbarzadeh-Khiavi M, Olfati AH, Safary A. Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases. Advanced Pharmaceutical Bulletin. 2026;16(2):332-342. doi:10.34172/apb.46844

BibTeX
@article{AkbarzadehKhiavi2026,
  author = {Akbarzadeh-Khiavi, Mostafa and Olfati, Amir-Hossein and Safary, Azam},
  title = {Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases},
  journal = {Advanced Pharmaceutical Bulletin},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {332--342},
  doi = {10.34172/apb.46844}
}
Kostenlos starten →